PreSENTIA hereditary cancer test panels can detect numerous inherited genetic changes (mutations) that could cause cancer in the future.
PreSENTIA offers an extensive portfolio of 19 hereditary cancer test panels. Each panel focuses on a set of genes that determine someone’s chances of developing a specific cancer in the future. The genetic changes in the genes that could cause cancer are inherited from parents to their children, and are present from birth. Knowing that a person carries one of these genetic mutations can help them take preventative measures and plan a more informed clinical management. As a result, early detection of cancer can be achieved – which increases the chances of successful treatment – or prevention.
WHAT IS CANCER?
Cancer is the rapid and uncontrollable growth of abnormal cells. It is the second leading cause of death, responsible for 1 out of 6 deaths globally. World Health Organization (WHO) recommends that cancer mortality can be significantly reduced by early detection and proper clinical management of cancers.
HOW DOES CANCER DEVELOP?
Cancer develops after certain genes that are responsible for keeping our body healthy undergo changes that cause them to become ‘faulty’. A cancer can be:
SPORADIC: Mutations in the genes causing cancer accumulate over time due to risk factors like tobacco, viruses (such as HPV), and environmental factors. These mutations cannot be inherited.
HEREDITARY: These mutations exist from birth. They run in families and can be passed down from parents to their children.
Inherited genetic mutations make up for 5-10% of all cancers.
WHAT SHOULD I ASK MY DOCTOR?
What are germline mutations?
Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.
What is a hereditary screening test?
A hereditary screening test checks if an individual has an inherited gene mutation in a gene with high cancer susceptibility.
If you or a family member were diagnosed with hereditary cancer, or a genetic change that is linked to cancer, there's a high chance other members of your family carry the genetic change as well. Each individual could be affected by cancer at different age, with wide range of severity, and by different cancer types.
WHO IS THIS TEST FOR?
Identifying the genetic change that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning, avoiding risk factors and informing family members of their risk.
According to genetic testing guidelines* for cancer, people who might benefit from genetic testing are those that have:
- Family members with cancer in the same side of the family
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
- Personal or family history of a hereditary cancer syndrome
Your healthcare provider will also take into account your medical family history, ethnicity and any physical findings present linked to cancer before recommending PreSENTIA to you.
* Data adapted from: American Cancer Society, National Cancer Institute, American Society of Clinical Oncology and American College of Obstetricians and Gynecologists.
HOW DOES PreSENTIA HELP ME?
PreSENTIA panels test for numerous genetic changes that are responsible for causing hereditary cancers. If you want to know more about your cancer risks, or if you have been already diagnosed with cancer and you want to know whether your cancer is hereditary, PreSENTIA can help.
- Targeted cancer monitoring – recommended screening tests at key time intervals to detect cancer early, when treatment is more beneficial
- Prevention of cancer by prophylactic measures
- Actionable information for family members that might carry the same gene
- Improved classification of the disease for better clinical management
- Drug therapy (chemoprevention)
WHY CHOOSE THE PreSENTIA TEST?
- Assesses clinically important mutations
- Ability to select the best panel for you
- Reliable technology
- Short turn-around time
- Safe and easy to perform
WHAT ARE ‘HEREDITARY CANCER SYNDROMES’?
Hereditary cancer syndromes are also known as cancer predisposing syndromes, as patients with these syndromes have an elevated risk of developing specific cancers in the future. These conditions occur when genes with critical roles in keeping our body healthy are mutated, causing a variety of symptoms and potentially affecting the quality of life. They can be inherited from one generation to the other.
Hereditary cancer syndromes characteristics
- Multiple cancer types
- Repeated cancers
- Young age of cancer onset
If you have cancer in your family history and want to know about your own risk, PreSENTIA can help. By identifying the mutated genes that could cause hereditary cancer syndromes, PreSENTIA can provide information that could help in clinical management. If you have been diagnosed with cancer and have any of the above characteristics, you might also have a hereditary cancer syndrome. Identifying this can help reveal how and why your cancer was caused.
HOW ACCURATE IS IT?
TARGETED TECHNOLOGY
By focusing only on the genetic changes tested, PreSENTIA is accurate and precise.
HIGH READ DEPTH
PreSENTIA analyzes the locations of the genetic changes hundreds of times, making the test results more sensitive and reliable.
WHAT DOES IT TEST FOR?
HEREDITARY CANCER PANELS
-
BREAST & GYNECOLOGICAL
26
HEREDITARY BREAST/GYNECOLOGICAL CANCER PANEL
Description
Hereditary Breast/Gynecological cancer panel tests for numerous germline mutations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for breast/gynaecological cancers are those that have:
- Several family members in the same side of the family with cancer
- Family members with early cancer onset
- Family members with rare cancer types
- A family member with multiple cancers
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- Personal history of previous malignancies
No of Genes Tested
26
No of related hereditary cancer syndromes
12
Genes Tested
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
- DICER 1 syndrome (DICER1)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary diffuse gastric syndrome (CDH1)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- MUTYH-associated polyposis syndrome (MUTYH)
- Peutz-Jeghers syndrome (STK11)
- Polymerase proofreading associated syndrome (POLD1, POLE)
- PTEN hamartoma syndrome (PTEN)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
BARD1, BRIP, MRE11, NBN, PALB2, RAD50, RAD51C, RAD51D, SMARCA4
-
BREAST / GYN GUIDELINES - BASED
19
HEREDITARY BREAST/GYNECOLOGICAL GUIDELINES-BASED CANCER PANEL
Description
Hereditary Breast/Gynecological cancer guidelines-based panel tests for numerous germline mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:
- Several family members in the same side of the family with cancer
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
19
No of related hereditary cancer syndromes
9
Genes Tested
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, STK11
Disorders associated with this panel:
- Ataxia telangiectasia syndrome (ATM)
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary diffuse gastric syndrome (CDH1)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Peutz-Jeghers syndrome (STK11)
- PTEN Hamartoma syndrome (PTEN)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
BARD1, BRIP, NBN, PALB2, RAD51C, RAD51D
-
BREAST
HIGH-RISK7
HEREDITARY BREAST HIGH-RISK CANCER PANEL
Description
Hereditary Breast High-Risk cancer panel tests for numerous germline mutations that are associated with a high risk for developing Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:
- Several family members in the same side of the family with cancer
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
7
No of related hereditary cancer syndromes
5
Genes Tested
BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53
Disorders associated with this panel:
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary diffuse gastric syndrome (CDH1)
- Li-Fraumeni syndrome (TP53)
- Peutz-Jeughers syndrome (STK11)
- PTEN hamartoma syndrome (PTEN)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
PALB2
-
BRCA1 / BRCA2
2
HEREDITARY BRCA1 / BRCA2 CANCER PANEL
Description
Hereditary BRCA1/BRCA2 cancer panel tests for germline mutations in the BRCA1 and BRCA2 genes that could cause specific cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers caused by mutations in the BRCA1/BRCA2 genes are those that have:
- Several family members with cancer in the same side of the family
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
2
No of related hereditary cancer syndromes
1
Genes Tested
BRCA1, BRCA2
Disorders associated with this panel:
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
-
COLORECTAL
17
HEREDITARY COLORECTAL CANCER PANEL
Description
Hereditary Colorectal cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:
- At least 1 first-degree family member with colorectal cancer
- Personal or family history of colorectal polyps or colorectal cancer
- Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
- Family members diagnosed with cancer at a young age
- Family members diagnosed with rare forms of cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- Personal history of previous malignancies
No of Genes Tested
17
No of related hereditary cancer syndromes
12
Genes Tested
APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
Disorders associated with this panel:
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- PTEN Hamartoma syndrome (PTEN)
- Peutz-Jeghers syndrome (STK11)
- Hereditary diffuse gastric syndrome (CDH1)
- MUTYH-associated polyposis syndrome (MUTYH)
- Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
- Polymerase Proofreading Associated syndrome (POLD1, POLE)
- Hereditary mixed polyposis syndrome (GREM1)
- Juvenile Polyposis syndrome (SMAD4, BMPR1A)
- Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2)
-
COLORECTAL
HIGH-RISK10
HEREDITARY COLORECTAL HIGH-RISK CANCER PANEL
Description
Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:
- At least 1 first-degree family member with colorectal cancer
- Personal or family history of colorectal polyps or colorectal cancer
- Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
- Family members diagnosed with cancer at a young age
- Family members diagnosed with rare forms of cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
10
No of related hereditary cancer syndromes
6
Genes Tested
APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11
Disorders associated with this panel:
- Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Juvenile polyposis syndrome (SMAD4, BMPR1A)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- MUTYH-associated polyposis syndrome (MUTYH)
- Peutz-Jeghers syndrome (STK11)
-
COLORECTAL
NON-POLYPOSIS5
HEREDITARY COLORECTAL NON-POLYPOSIS CANCER PANEL
Description
Hereditary Colorectal Non-Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:
- At least 1 first-degree family member with colorectal cancer
- Personal or family history of colorectal polyps or colorectal cancer
- Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
- Family members diagnosed with cancer at a young age
- Family members diagnosed with rare forms of cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
5
No of related hereditary cancer syndromes
2
Genes Tested
EPCAM, MLH1, MSH2, MSH6, PMS2
Disorders associated with this panel:
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
-
COLORECTAL POLYPOSIS SYNDROME
7
HEREDITARY COLORECTAL POLYPOSIS CANCER PANEL
Description
Hereditary Colorectal Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary polyposis colorectal cancers are those that have:
- At least 1 first-degree family member with colorectal cancer
- Personal or family history of colorectal polyps or colorectal cancer
- Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
- Family members diagnosed with cancer at a young age
- Family members diagnosed with rare forms of cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
7
No of related hereditary cancer syndromes
5
Genes Tested
APC, BMPR1A, MUTYH, POLD1, POLE, SMAD4,STK11
Disorders associated with this panel:
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Juvenile polyposis syndrome (SMAD4, BMPR1A)
- MUTYH-associated polyposis syndrome (MUTYH)
- Peutz-Jeghers syndrome (STK11)
- Polymerase proofreading associated syndrome (POLD1, POLE)
-
MYELODYSPLASTIC SYNDROME/LEUKEMIA
24
HEREDITARY MYELODYSPLASTIC SYNDROME / LEUKEMIA CANCER PANEL
Description
Hereditary Myelodysplastic syndrome / Leukemia cancer panel tests for numerous germline mutations that could cause blood cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukemias are those that have:
- Family history of a hereditary cancer syndrome associated with leukemia
- Personal history of a hereditary cancer syndrome associated with leukemia
- An identical twin who developed leukemia in the first year of life
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
24
No of related hereditary cancer syndromes
6
Genes Tested
ATM, BRCA1, BRCA2, BRIP1, EPCAM, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, SLX4, TP53
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
- Hereditary breast & ovarian syndrome (BRCA1 & BRCA2)
- Li-Fraumeni syndrome (TP53)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
-
GASTRIC
14
HEREDITARY GASTRIC CANCER PANEL
Description
Hereditary Gastric cancer panel tests for numerous inherited germline mutations that could cause gastric (stomach) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for gastric cancers are those that have:
- Several family members in the same side of the family with gastric cancer
- Personal or family history of a hereditary cancer syndrome linked to gastric cancer
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
14
No of related hereditary cancer syndromes
8
Genes Tested
APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53
Disorders associated with this panel:
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
- Hereditary diffuse gastric syndrome (CDH1)
- Hereditary Paraganglioma-Pheochromocytoma syndrome (SDHB, SDHC, SDHD)
- Juvenile Polyposis syndrome (SMAD4, BMPR1A)
- Li-Fraumeni syndrome (TP53)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Peutz-Jeghers syndrome (STK11)
-
PROSTATE
15
HEREDITARY PROSTATE CANCER PANEL
Description
Hereditary Prostate cancer panel tests for numerous germline mutations that could cause prostate cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:
- Several first-degree family members with prostate cancer
- Family members diagnosed with prostate cancer at young age
- Family members diagnosed with other cancer types, including breast, ovarian and pancreatic
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
15
No of related hereditary cancer syndromes
6
Genes Tested
ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, TP53
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
- PTEN hamartoma syndrome (PTEN)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
HOXB13, NBN, PALB2, RAD51D
-
PANCREATIC
17
HEREDITARY PANCREATIC CANCER PANEL
Description
Hereditary Pancreatic cancer panel tests for numerous germline mutations that could cause pancreatic cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for pancreatic cancers are those that have:
- Several family members in the same side of the family with pancreatic cancer
- First-degree relative who developed pancreatic cancer before the age of 50
- Personal or family history of a hereditary cancer syndrome linked to pancreatic cancer
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
17
No of related hereditary cancer syndromes
10
Genes Tested
APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), EPCAM, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, STK11, TP53
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
- Juvenile polyposis syndrome (SMAD4, BMPR1A)
- Li-Fraumeni syndrome (TP53)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Multiple endocrine neoplasia type 1 (MEN1)
- Peutz-Jeghers syndrome (STK11)
-
RENAL
13
HEREDITARY RENAL CANCER PANEL
Description
Hereditary Renal cancer panel tests for numerous germline mutations that could cause renal (kidney) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary renal cancers are those that have:
- Family members that have had renal cancer, especially at a young age
- Family members with renal cancer in both kidneys
- Family members diagnosed with a hereditary cancer syndrome associated with renal cancer
- Personal history of a hereditary cancer syndrome associated with renal cancer
- Multiple cancers in the same family member
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
13
No of related hereditary cancer syndromes
7
Genes Tested
BAP1, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, SDHAF2, SDHB, SDHC, SDHD, TP53, VHL
Disorders associated with this panel:
- BAP1 mutation associated disease (BAP1)
- Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHC, SDHD)
- Li-Fraumeni syndrome (TP53)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- PTEN hamartoma syndrome (PTEN)
- Von-Hippel Lindau syndrome (VHL)
-
SKIN (XP-ASSOCIATED)
9
HEREDITARY SKIN (XP-ASSOCIATED) CANCER PANEL
Description
Hereditary Xeroderma Pigmentosum-related cancer panel tests for numerous germline mutations that could cause skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for Xeroderma Pigmentosum-related skin cancers are those that have:
- Family or personal history of a hereditary cancer syndrome associated with skin cancers
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
9
No of related hereditary cancer syndromes
1
Genes Tested
DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC
Disorders associated with this panel:
- Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)
-
FAMILIAL MELANOMA
7
HEREDITARY FAMILIAL MELANOMA CANCER PANEL
Description
Hereditary Familial Melanoma cancer panel tests for numerous germline mutations that could cause familial melanoma skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary melanoma cancers are those that have:
- At least two first-degree family member who have had metastatic melanoma
- At least one family member has had multiple melanomas
- Family or personal history of a hereditary cancer syndrome associated with melanoma
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
7
No of related hereditary cancer syndromes
5
Genes Tested
BAP1, BRCA2, CDK4, CDKN2A (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), PTEN, RB1, TP53
Disorders associated with this panel:
- BAP1 mutation associated disease (BAP1)
- Hereditary pancreatic-melanoma syndrome (CDKN2A, CDK4)
- Li-Fraumeni syndrome (TP53)
- PTEN hamartoma syndrome (PTEN)
- Retinoblastoma (RB1)
-
PARAGANGLIOMA / PHEOCHROMOCYTOMA
6
HEREDITARY PARAGANGLIOMA / PHEOCHROMOCYTOMA CANCER PANEL
Description
Hereditary Paraganglioma / Pheochromocytoma cancer panel tests for germline mutations in numerous genes that could cause Paraganglioma or Pheochromocytoma cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for Paraganglioma or Pheochromocytoma cancers are those that have:
- Family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
6
No of related hereditary cancer syndromes
3
Genes Tested
RET, SDHAF2, SDHB, SDHC, SDHD, VHL
Disorders associated with this panel:
- Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHD, SDHC)
- Multiple endocrine neoplasia type 2 (RET)
- Von-Hippel Lindau syndrome (VHL)
-
PARATHYROID
1
HEREDITARY PARATHYROID CANCER PANEL
Description
Hereditary Parathyroid cancer panel tests for germline mutations in the MEN1 gene that could cause parathyroid cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:
- At least two first-degree family member who have had parathyroid tumors
- A personal or family history of a hereditary cancer syndrome associated with parathyroid cancer
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
1
No of related hereditary cancer syndromes
1
Genes Tested
MEN1
Disorders associated with this panel:
- Multiple endocrine neoplasia type 1 (MEN1)
-
THYROID
1
HEREDITARY THYROID CANCER PANEL
Description
Hereditary Thyroid cancer panel tests for germline mutations in the RET gene that could cause medullary thyroid cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:
- At least one first-degree family member who has had thyroid cancer
- A personal or family history of a hereditary cancer syndrome associated with thyroid cancer
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
No of Genes Tested
1
No of related hereditary cancer syndromes
1
Genes Tested
RET
Disorders associated with this panel:
- Multiple endocrine neoplasia type 2 (RET)
-
PAN-CANCER
62
HEREDITARY PAN-CANCER PANEL
Description
Hereditary Pan-Cancer panel tests for numerous germline mutations in a total of 62 genes that could cause several cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.
Who is this test for?
According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:
- Several family members in the same side of the family with cancer
- Multiple cancers in the same family member
- Family members with early cancer onset
- Family members with rare cancer types
- Family members with an unusual type of cancer (breast cancer in a male)
- Personal or family history of a hereditary cancer syndrome
- A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
- History of previous malignancies
No of Genes Tested
62
No of related hereditary cancer syndromes
24
Genes Tested
APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), CHEK2, DDB2, DICER1, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GREM1, HOXB13, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, POLH, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, STK11, TP53, VHL, XPA, XPC
Disorders associated with this panel:
- Ataxia-telangiectasia syndrome (ATM)
- BAP1 mutation associated disease (BAP1)
- Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
- DICER 1 syndrome (DICER1)
- Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
- Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
- Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
- Hereditary diffuse gastric syndrome (CDH1)
- Hereditary mixed polyposis syndrome (GREM1)
- Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
- Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB)
- Juvenile polyposis syndrome (SMAD4, BMPR1A)
- Li-Fraumeni syndrome (TP53)
- Li-Fraumeni syndrome 2 (CHEK2)
- Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
- Multiple endocrine neoplasia type 1 (MEN1)
- Multiple endocrine neoplasia type 2 (RET)
- MUTYH-associated polyposis syndrome (MUTYH)
- Peutz-Jeghers syndrome (STK11)
- Polymerase proofreading associated syndrome (POLD1, POLE)
- PTEN hamartoma syndrome (PTEN)
- Retinoblastoma (RB1)
- Von-Hippel Lindau syndrome (VHL)
- Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)
The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:
BARD1, MRE11, RAD50, SMARCA4, HOXB13, NBN, RAD51D
-
Hereditary Cancer Syndromes
Cancer Predisposing Syndromes & Associated Genes Associated Cancers Li-Fraumeni syndrome
TP53Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain, Lung, Leukemia Li-Fraumeni syndrome 2
CHEK2Breast, Sarcoma, Brain Hereditary breast and ovarian cancer syndrome
BRCA1, BRCA2Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus Familial adenomatous polyposis/Attenuated familial adenomatous polyposis syndrome
APCGastric, Pancreatic, Colorectal, Osteomas, Small Bowel MUTYH-associated polyposis syndrome
MUTYHColorectal Lynch syndrome
MLH1, MSH2, MSH6, PMS2, EPCAMColorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal PTEN hamartoma syndrome
PTENBreast, Endometrial, Colorectal, Melanoma, Renal Peutz-Jeghers syndrome
STK11Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic Juvenile polyposis syndrome
SMAD4, BMPR1AColorectal, Gastric, Pancreatic Fanconi anemia syndrome
FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51CLeukemia, Tumors of the head & neck, Gastrointestinal Von-Hippel Lindau syndrome
VHLRenal, Paragangliomas, Pheochromocytomas Retinoblastoma
RB1Eye, Bone, Uveal Melanoma Xeroderma pigmentosum syndrome
DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA,XPCNon-Melanoma & Melanoma Hereditary melanoma-pancreatic cancer syndrome
CDKN2A, CDK4Melanoma, Pancreatic Hereditary diffuse gastric syndrome
CDH1Gastric & Breast DICER 1 syndrome
DICER1Lung, Renal, Ovarian, Thyroid Polymerase Proofreading Associated syndrome
POLD1, POLEColorectal & Endometrial Multiple Endocrine Neoplasia (MEN) syndrome type 1
MEN1Parathyroid & Pancreatic Multiple Endocrine Neoplasia (MEN) syndrome type 2
RETThyroid & Pheochromocytoma BAP1 Mutation associated disease
BAP1Skin, Eye, Renal, Mesothelioma Ataxia-telangiectasia syndrome
ATMLeukemia & Lymphoma Hereditary-mixed polyposis syndrome
GREM1Colorectal Constitutional mismatch repair syndrome
MSH2, MSH6, MLH1, PMS2Hematologic malignancies, Brain, Gastrointestinal, Colorectal Hereditary Paraganglioma – Pheochromocytoma syndrome
SDHAF2, SDHB, SDHC, SDHDRenal, Thyroid, Paragangliomas, Pheochromocytomas
HOW CAN I TAKE PreSENTIA?
-
CONSULT WITH YOUR HEALTHCARE
PROVIDER ON WHICH PANEL IS
IDEAL FOR YOU
-
YOUR DOCTOR WILL COLLECT
A BUCCAL SWAB SAMPLE FROM YOU
THE SAMPLE WILL BE SENT TO
OUR LABORATORY
THE SAMPLE WILL BE ANALYZED
IN OUR LABORATORY
RESULTS WILL BE SENT TO YOUR HEALTHCARE PROVIDER WITHIN 2-3 WEEKS
FAQ
-
What are mutations?
A mutation is a change that happens in the DNA that could possibly affect the health of an individual.
-
What is genetic testing?
Genetic testing identifies changes in the DNA.
-
What is cancer susceptibility and cancer predisposition?
Cancer susceptibility, or predisposition, is the likelihood of being affected by cancer in the future. This depends on an individual’s DNA. There are certain inherited, genetic changes that raise someone’s risk of developing cancer in the future. This is because these changes happen in genes that are responsible for protecting the body from disease, and when they are affected, their protective role halts.
-
What are germline mutations?
Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. Germline mutations are different from somatic mutations, which occur when a genetic change happens in the DNA due to exposure to risk factors – after a person is born. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.
-
What is hereditary screening?
A hereditary screening test checks if an individual has an inherited, genetic change in a gene with high cancer susceptibility from birth. Identifying the mutation that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning and avoiding risk factors.
-
How do I decide what is the best panel for me?
Your healthcare provider will recommend the best panel for you after considering the types of cancers that have affected your family members, any genetic changes that have already been diagnosed in one of your family members, and any symptoms exhibited. Consult with your healthcare provider on which panel is ideal.
NIPD Genetics - Privacy Policy
General Statement
NIPD Genetics is a leading, innovative biotechnology company that designs, develops, and provides a broad spectrum of healthcare services to its customers through its expansive portfolio of molecular and clinical laboratory tests in all disciplines.
At NIPD Genetics we are committed to protecting and respecting our customer’s privacy and personal information. Personal information or personal data means any information that identifies, relates to, describes, is capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular individual, such as name, identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that individual.
NIPD Genetics collects and processes your personal information according to the General Data Protection Regulation (EU) 2016/679 and the Cypriot law providing for the protection of natural persons with regards to the processing of personal data and for the free movement of such data (L. 125(I)/2018). The following principles lie at the heart of our approach to handling personal data:
- Lawfulness, fairness and transparency – We collect and process personal data in a lawful and transparent manner and clearly communicate to our customers how their personal data will be used.
- Purpose limitation – We only use personal data for the purpose for which they have been collected.
- Data minimization – We only collect the data that is absolutely necessary in relation to the purposes for which they are processed.
- Accuracy – We take every reasonable step to ensure that personal data collected are accurate and up to date.
- Storage limitation – We do not keep personal data for longer than it is needed. Personal data are periodically reviewed and erased if they are not needed or anonymized and stored for scientific research purposes.
- Integrity and confidentiality (security) – Appropriate technical and organizational measures are in place to ensure that personal data are adequately protected from any unauthorised or illegal processing and accidental loss, destruction or damage.
- Accountability – We, at NIPD Genetics, are committed to compliance with all legal requirements and promote internal practices to achieve the highest standards for personal data privacy.
NIPD Genetics has appointed a Data Protection Officer (DPO) who is responsible for overseeing and ensuring that personal information is collected and processed in line with these principles. The contact details of the Data Protection Officer (DPO) can be found below:
Email address: dpo@nipd.com
Postal address: 31 Neas Engomis street, 2409 Engomi, Nicosia, Cyprus
Telephone number: + 357 22266888
By accessing or using our products or services, or by transmitting information to us by email or other electronic means, you accept our policies, procedures and practices described in this Privacy Policy. If you do not agree with our policies, procedures and practices as described, you can choose not to access or use our products or services or not to transmit personal information to us.
This Privacy Policy applies to NIPD Genetics facilities, its websites www.nipd.com, www.nipdlabs.com, www.nipdlabs.com.cy and their subdomains, that link to this privacy pol icy.
PERSONAL INFORMATION COLLECTION AND PROCESSING
We collect and process several types of personal information from and about users of our websites and of our products and services, including:
- Personal and sensitive information: some of our products and services may involve testing of biological samples that we or our customers use to create test reports, genotyping or sequencing services for research or clinical purposes and the receipt, creation, or analysis of genomic or other data derived from samples, including through our customer’s use of our software as a service product. In receiving samples and providing our products and services, we may obtain your name and surname, date of birth, email address, home address, telephone number, gender, ethnicity and other health related information.
- Computer, device and browsing information: as you interact with our products and services online, including this website, we may use automatic data collection technologies to collect certain information about your computer or device, as well as browsing actions and usage patterns. This data may include your IP address, browser type or version. The technologies we use for this automatic data collection may include cookies. You can control cookies by adjusting your cookies settings.
Information about children
If you are under 18 years of age, do not register on our website or provide any information about yourself to us. We do not provide our products or services directly to children or proactively collect their personal information. Despite this prohibition, it is possible that we may sometimes be given information about children while handling samples from our customers in our clinical labs, or through use of our products and services by our customers and partners. If we become aware that we have inadvertently collected personal information from children under the age of 18, without parental consent, we will take the necessary steps to delete it as soon as possible in compliance with applicable laws.
LEGAL BASIS FOR PROCESSING OF YOUR PERSONAL INFORMATION
Your personal information is collected by NIPD Genetics for the following purposes:
- To provide you with our products and services, respond to your inquiries or fulfill your requests and otherwise manage your relationship with us. The legal basis for processing is to meet the requirements of a contract, to comply with our legal obligations and/or because we have a legitimate interest in responding to requests for information about our products and services.
- To communicate with you about content and product offerings, newsletters and event invitations which are relevant to your interests and in line with your preferences. The legal basis for processing is the individual’s explicit consent prior to sending the information and managing individuals preferences.
- To process and respond to complaints. The legal basis for processing is to meet a legal obligation.
- To monitor and record information relating to the use of our products and services, including our website. The legal basis for processing is our legitimate interest in order to improve our products and services and our website for individuals.
To provide our products and services, NIPD Genetics may collect, receive and process biological samples to isolate and sequence DNA. NIPD Genetics may then store resulting genetic information and use genetic information to provide our products and services. In some cases, NIPD Genetics may provide interpretations of genetic information on behalf of its customers, including healthcare providers. This is only done pursuant to a written contract or a Sample Information Form with a patient’s informed consent and is subject to applicable legal and ethical safeguards.
This sensitive information described above is collected by NIPD Genetics for the following purposes:
- To provide support and maintenance services to customers who use our products and services – The legal basis for processing is to meet the requirements of a contract.
- To provide genotyping and sequencing services and analysis for our customers, including healthcare providers. The legal basis of this processing is to meet the requirements of a contract or as allowed in the Sample Information Form with a patient’s informed consent.
- To conduct genotyping and sequencing services and analysis for quality control, process and product development and improvements, and optimization in our labs to reflect quality improvements and advances in our technology. The legal basis for processing is the patient’s informed consent given through the Sample Information Form.
Transfer of Data
Your information, including personal data, may be transferred to - and maintained on - computers located outside your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.
If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.
Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.
NIPD Genetics will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal information will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.
Disclosure of Data
NIPD Genetics complies with the General Data Protection Regulation and will not sell or trade your personal information.
NIPD Genetics may disclose your personal information in the good faith that such action is necessary:
- To comply with a legal obligation
- To protect and defend the rights or property of NIPD Genetics
- To prevent or investigate possible wrongdoing in connection with our products and services
- To protect against legal liability
COOKIES AND OTHER TRACKING TECHNOLOGIES
Cookies are files with small amount of data which may include an anonymous unique identifiers. Cookies are sent to your browser when you visit a website and stored on your device. Tracking technologies used on the website are beacons, tags and scripts, to collect and track information and to improve and analyze our websites.
We use cookies and similar tracking technologies to track the activity on our websites and collect certain information. This includes information about the computer or device you are using, such as Internet protocol (IP) address, information about the browser type or version, the pages of our website that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.
You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our websites.
Examples of Cookies we may use:
Session Cookies. We use Session Cookies to operate our websites.
Preference Cookies. We use Preference Cookies to remember your preferences and various settings.
Security Cookies. We use Security Cookies for security purposes.
Visitor behavior cookies. To understand how visitors use and navigate the websites
Keyword cookies. To understand how visitors discover the websites.
ANALYTICS
We may use third-party Service Providers to monitor and analyze the use of our websites.
Google Analytics
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.
You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.
For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page
SECURITY OF DATA
We are committed to protecting the security of the information we collect, and we take reasonable physical, technical, and administrative safeguards such as data anonymization and encryption to help protect personal information from unauthorized or inappropriate access or use. It is your responsibility to protect the confidentiality of your passwords, and any other access features associated with your access or use of the website or our products and services, as well as to adhere to any applicable Terms of Use or other contract between us and you or your organization.
PERSONAL DATA RETENTION
We may retain collected information even after you remove it from the website, our Services, or our Products, to comply with applicable law, to resolve disputes, to enforce any rights in connection with the website, our Services, or our Products, and to use as provided in this Privacy Policy, the Terms of Use, or an applicable contract between us and you or your organization. How long we retain specific personal information varies depending on the purpose for its use and we may delete or retain your personal information in accordance with applicable law.
SERVICE PROVIDERS
We may employ third party companies and individuals to facilitate, maintain or operate our websites (“Service Providers”), to provide the websites on our behalf, to perform service-related services or to assist us in analyzing how our websites are used.
These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.
LINKS TO OTHER SITES
Our websites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.
We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.
CHANGES TO THIS PRIVACY POLICY
This Privacy Policy may be updated from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.
We will let you know via email and/or a prominent notice on our website, prior to the change becoming effective and update the “effective date” at the bottom of this Privacy Policy.
You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.
YOUR LEGAL RIGHTS
NIPD Genetics ensures that it can respond immediately to requests that you make for the exercise of your legal rights in accordance with data protection laws. These rights are as follows:
- The right to withdraw consent at any time – in cases where processing is based on your consent
- The right of access – at any given time you have the right to know what information about you we hold and receive information about the processing activities we perform
- The right to rectify – you have the right to correct, amend and complete personal data that is incomplete
- The right to erasure (“right to be forgotten”) – you can request that your personal information is deleted
- The right to object – you can object at any time to our processing of your personal information
- The right to restriction of processing – this applies in the event:
- You dispute the accuracy of your personal information and until it is verified
- You oppose to the deletion of personal data and ask instead to delete the use of it
- The personal information is no longer necessary for us
- You object to the processing and we are considering whether our legitimate grounds for processing prevail over the reasons you oppose to the processing
- The right to data portability – at any given time you have the right to receive the personal information we hold about you in a structured, commonly used and machine-readable format (pdf, word etc.). You also have the right to request that these data are transferred to another service in a safe and secure way
You also have the right to lodge a complaint at any time to the Office of the Commissioner for Personal Data Protection.
We encourage you to contact us, should you wish to practice any of your legal rights or you have any questions about this Privacy Policy, by sending an email to NIPD Genetics’ Data Protection Officer at dpo@nipd.com.
Effective date: 18/06/2021
Ok got it!